Cardiff Oncology, Inc. (CRDF)
NASDAQ: CRDF · Real-Time Price · USD
4.165
+0.585 (16.34%)
Mar 12, 2025, 12:09 PM EST - Market open
Cardiff Oncology Stock Forecast
Stock Price Forecast
The 4 analysts with 12-month price forecasts for Cardiff Oncology stock have an average target of 12, with a low estimate of 8.00 and a high estimate of 17. The average target predicts an increase of 188.12% from the current stock price of 4.17.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Cardiff Oncology stock from 4 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Oct '24 | Nov '24 | Dec '24 | Jan '25 | Feb '25 | Mar '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 2 | 3 | 3 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 3 | 3 | 3 | 3 | 4 | 4 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $13 → $17 | Strong Buy | Maintains | $13 → $17 | +308.16% | Feb 28, 2025 |
| Piper Sandler | Piper Sandler | Buy Maintains $7 → $10 | Buy | Maintains | $7 → $10 | +140.10% | Dec 13, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $14 → $13 | Strong Buy | Maintains | $14 → $13 | +212.12% | Nov 8, 2024 |
| Craig-Hallum | Craig-Hallum | Strong Buy Initiates $8 | Strong Buy | Initiates | $8 | +92.08% | Sep 6, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $14 | Strong Buy | Reiterates | $14 | +236.13% | May 6, 2024 |
Financial Forecast
Revenue This Year
340.00K
from 683.00K
Decreased by -50.22%
Revenue Next Year
102.00K
from 340.00K
Decreased by -70.00%
EPS This Year
-0.92
from -0.95
EPS Next Year
-1.12
from -0.92
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 735,000 | 420,000 | 420,000 | ||
| Avg | 339,997 | 102,000 | 153,000 | ||
| Low | n/a | n/a | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 7.6% | 23.5% | 311.8% | ||
| Avg | -50.2% | -70.0% | 50.0% | ||
| Low | - | - | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -0.74 | -0.89 | -1.80 | ||
| Avg | -0.92 | -1.12 | -1.74 | ||
| Low | -1.29 | -1.47 | -1.68 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.